Aminopyridines
Anaplastic Lymphoma Kinase
/ antagonists & inhibitors
Antineoplastic Agents
/ adverse effects
Biomarkers, Tumor
/ antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Clinical Decision-Making
DNA Mutational Analysis
Disease Progression
Drug Resistance, Neoplasm
/ genetics
Humans
Lactams
Lactams, Macrocyclic
/ adverse effects
Lung Neoplasms
/ drug therapy
Mutation
Patient Selection
Progression-Free Survival
Protein Kinase Inhibitors
/ adverse effects
Pyrazoles
Risk Factors
Time Factors
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
pubmed:
21
3
2019
medline:
27
5
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib. We analyzed plasma DNA for Approximately one quarter of patients had In patients who have failed 1 or more second-generation ALK TKIs, lorlatinib shows greater efficacy in patients with
Identifiants
pubmed: 30892989
doi: 10.1200/JCO.18.02236
pmc: PMC6544460
doi:
Substances chimiques
Aminopyridines
0
Antineoplastic Agents
0
Biomarkers, Tumor
0
Lactams
0
Lactams, Macrocyclic
0
Protein Kinase Inhibitors
0
Pyrazoles
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
lorlatinib
OSP71S83EU
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1370-1379Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA164273
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
Clin Cancer Res. 2018 Aug 1;24(15):3539-3549
pubmed: 29691297
Cancer Discov. 2018 Jun;8(6):714-729
pubmed: 29650534
J Clin Oncol. 2016 Mar 1;34(7):661-8
pubmed: 26598747
PLoS One. 2015 Oct 16;10(10):e0140712
pubmed: 26474073
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40
pubmed: 21502504
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
J Clin Oncol. 2016 Oct 1;34(28):3375-82
pubmed: 27354477
Clin Cancer Res. 2012 Mar 1;18(5):1472-82
pubmed: 22235099
J Clin Oncol. 2017 Aug 1;35(22):2490-2498
pubmed: 28475456
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
Lancet Oncol. 2016 Feb;17(2):234-242
pubmed: 26708155
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779
pubmed: 29563138
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cancer Cell. 2015 Jul 13;28(1):70-81
pubmed: 26144315
JCO Precis Oncol. 2018;2018:null
pubmed: 29376144
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
J Med Chem. 2014 Jun 12;57(11):4720-44
pubmed: 24819116
JAMA Oncol. 2017 Jun 1;3(6):740-741
pubmed: 27541382